Forest Laboratories, Inc. (FRX) Obtains Six Months U.S. Pediatric Exclusivity for NAMENDA® and NAMENDA XR®
6/18/2014 10:22:46 AM
NEW YORK--(BUSINESS WIRE)--Forest Laboratories, Inc. (NYSE:FRX) announced today that the U.S Food and Drug Administration (FDA) has granted pediatric exclusivity for memantine hydrochloride. Based on this decision, an additional six months of U.S. market exclusivity will attach to the patents that are listed in FDA’s Orange Book for NAMENDA and NAMENDA XR.
Help employers find you! Check out all the jobs and post your resume.
comments powered by